HK Stock Market Move | IMMUNEONCO-B(01541) surged over 16%, Amonirufu subcutaneous formulation IMM0306S for the treatment of systemic lupus erythematosus was approved for IND.

IMMUNEONCO-B (01541) surged more than 16%, reaching 15.87% by the time of publication, at 4.38 Hong Kong dollars, with a trading volume of 9.4717 million Hong Kong dollars. On the news front, on March 4th, according to the official WeChat account of ImmuneOnco Biopharma, the company announced that its self-developed subcutaneous injection formulation of Amurifup (IMM0306S) for the treatment of systemic lupus erythematosus (SLE) has received official approval for clinical trial application (IND) from the National Medical Products Administration (NMPA) of China. This milestone development marks a significant breakthrough in ImmuneOnco's innovative drug development in the field of autoimmune diseases. The approval of the IND for the treatment of SLE with the subcutaneous injection formulation of Amurifup (IMM0306S) is the latest achievement in ImmuneOnco's intensive layout in the field of autoimmune diseases, and a significant manifestation of its "comprehensive flowering of the self-immunity pipeline" strategy. In recent years, leveraging the "mAb-Trap" technology platform, IMM0306 has made significant progress in multiple high-impact self-immune indications, building a rich and deep product portfolio.